Paper 107 - PEXIDARTINIB USE IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: AN ANALYSIS OF THE PHASE III RANDOMIZED ENLIVEN CLINICAL TRIAL ACCORDING TO SURGICAL HISTORY

Author(s)

• JH

  John H. Healey, MD

  Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College
  New York, New York, United States

  Slides

Co-Author(s)

• AW

  Andrew J. Wagner, MD, PhD

  MD, PhD
  Dana-Farber Cancer Institute
  Boston, Massachusetts, United States
• SS

  Silvia Stacchiotti, MD

  Medical Oncologist
  Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Lombardia, Italy
• MQ

  Meng Qian, PhD

  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• KT

  Kristen Tecson, PhD

  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States
• MW

  Margaret Wooddell, PhD, MBA

  Daiichi Sankyo, Inc.
  Basking Ridge, New Jersey, United States

Presenter(s)

• WT

  William D. Tap, MD

  Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College
  New York, New York, United States